PROCEPT BioRobotics Corporation (PRCT)

Market Cap	3.01B
Revenue (ttm)	249.12M
Net Income (ttm)	-90.19M
Shares Out	55.33M
EPS (ttm)	-1.70
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	629,803
Open	55.30
Previous Close	55.62
Day's Range	53.97 - 55.30
52-Week Range	47.04 - 103.81
Beta	1.10
Analysts	Strong Buy
Price Target	90.00 (+65.41%)
Earnings Date	Apr 24, 2025

About PRCT

PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery focusing on treating benign prostatic hyperplasia. It also provides HYDROS Robotic System, which provides Aquablation therapy image-guided robotic therapy to treat males suffering from lower urinary tract symptoms due to benign p...

• Industry: Medical Devices
• Sector: Healthcare
• IPO Date: Sep 15, 2021
• Employees: 756
• Stock Exchange: NASDAQ
• Ticker Symbol: PRCT
• Website: https://www.procept-biorobotics.com

Financial Performance

In 2024, PROCEPT BioRobotics's revenue was $224.50 million, an increase of 64.84% compared to the previous year's $136.19 million. Losses were -$91.41 million, -13.68% less than in 2023.

Analyst Forecast

According to 7 analysts, the average rating for PRCT stock is "Strong Buy." The 12-month stock price forecast is $90.0, which is an increase of 65.41% from the latest price.

Price Target

$90.0

(65.41% upside)

Analyst Consensus: Strong Buy